Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia

The most frequent subtype of acute myeloid leukemia (AML) is defined by mutations in the nucleophosmin 1 (NPM1) gene. Mutated NPM1 (ΔNPM1) is an attractive target for immunotherapy, since it is an essential driver gene and 4 bp frameshift insertions occur in the same hotspot in 30%–35% of AMLs, resu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Invest
Hlavní autoři: van der Lee, Dyantha I., Reijmers, Rogier M., Honders, Maria W., Hagedoorn, Renate S., de Jong, Rob C.M., Kester, Michel G.D., van der Steen, Dirk M., de Ru, Arnoud H., Kweekel, Christiaan, Bijen, Helena M., Jedema, Inge, Veelken, Hendrik, van Veelen, Peter A., Heemskerk, Mirjam H.M., Falkenburg, J.H. Frederik, Griffioen, Marieke
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355238/
https://ncbi.nlm.nih.gov/pubmed/30640174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI97482
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky